Summary
Multidrug resistance is a dramatic complication that can impede cancer treatment. Some cancer cells can become resistant to a cytostatic agent, survive and develop resistance to most agents available for chemotherapy. As multi-drug resistance is linked to sphingolipid metabolism, manipulating sphingolipid metabolism might be a way to circumvent the sensitization of cancer cells to chemotherapy. Two strategies seem particularly promising. One is to drive sphingolipid metabolism towards the production of proapoptotic lipid ceramide, which leads to cell death, and away from sphingosine-1-phosphate and glucosylceramide, which stimulate proliferation. The other is to alter the expression or activity of multidrug efflux pumps that in many cases supply the molecular basis for multidrug resistance.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
5. References
Bacso Z, Nagy H, Goda K, Bene L, Fenyvesi F, et al. (2004) Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A, 61, 105–116.
Boldin SA, Futerman AH (2000) Up-regulation of glucosylceramide synthesis upon stimulation of axonal growth by basic fibroblast growth factor. Evidence for post-translational modification of glucosylceramide synthase. J Biol Chem, 275, 9905–9909.
Borst P, Oude Elferink R (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem, 71, 537–592.
Boujaoude LC, Bradshaw-Wilder C, Mao C, Cohn J, Ogretmen B, et al. (2001) Cystic fibrosis transmembrane regulator regulates uptake of sphingoid base phosphates and lysophosphatidic acid: modulation of cellular activity of sphingosine 1-phosphate. J Biol Chem, 276, 35258–35264.
Bucher K, Besse CA, Kamau SW, Wunderli-Allenspach H, Kramer SD (2005) Isolated rafts from adriamycin-resistant P388 cells contain functional ATPas-es and provide an easy test system for P-glycoprotein-related activities. Pharm Res, 22, 449–457.
De Rosa MF, Sillence D, Ackerley C, Lingwood C (2004) Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J Biol Chem, 279, 7867–7876.
Futerman AH, Hannun YA (2004) The complex life of simple sphingolipids. EM-BO Rep, 5,777–782.
Ghetie MA, Marches R, Kufert S, Vitetta ES (2004) An anti-CD19 antibody inhibits the interaction between P-glycoprotein (P-gp) and CD19, causes P-gp to translocate out of lipid rafts, and chemosensitizes a multidrug-resistant (MDR) lymphoma cell line. Blood, 104, 178–183.
Gouazé V, Liu YY, Prickett CS, Yu JY, Giuliano AE, Cabot MC (2005) Gluco-sylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res, 65,3861–3867.
Gómez-Muñoz A, Kong JY, Parhar K, Wang SW, Gangoiti P, et al. (2005) Ceramide-1-phosphate promotes cell survival through activation of the phosphatidylinositol 3-kinase/protein kinase B pathway. FEBS Lett, 579, 3744–3750.
Higgins CT, Gottesman MM (1992) Is the multidrug transporter a flippase? Trends Biochem Sci, 17, 18–21.
Huitema K, Van Den Dikkenberg J, Brouwers JF, Holthuis JC (2004) Identification of a family of animal sphingomyelin synthases. Embo J, 23, 33–44.
Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H, Kok JW (2004) MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer, 110, 511–522.
Kohyama-Koganeya A, Sasamura T, Oshima E, Suzuki E, Nishihara S, et al. (2004) Drosophila glucosylceramide synthase: a negative regulator of cell death mediated by proapoptotic factors. J Biol Chem, 279, 35995–36002.
Lavie Y, Fiucci G, Liscovitch M (2001) Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv Drug Deliv Rev, 49, 317–323.
Ling V (1975) Drug resistance and membrane alteration in mutants of mammalian cells. Can J Genet Cytol, 17, 503–515.
Norris-Cervetto E, Callaghan R, Platt FM, Dwek RA, Butters TD (2004) Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J Biol Chem, 279, 40412–40418.
Plo I, Lehne G, Beckstrom KJ, Maestre N, Bettaieb A, et al. (2002) Influence of ceramide metabolism on P-glycoprotein function in immature acute myeloid leukemia KG1a cells. Mol Pharmacol, 62, 304–312.
Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F, Sonnino S (2003) Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem, 278, 5574–5583.
Raggers RJ, van Helvoort A, Evers R, van Meer G (1999) The human multidrug resistance protein MRP1 translocates sphingolipid analogs across the plasma membrane. J Cell Sci, 112, 415–422.
Reyes CL, Chang G (2005) Structure of the ABC transporter MsbA in complex with ADP.vanadate and lipopolysaccharide. Science, 308, 1028–1031.
Rosenberg MF, Callaghan R, Modok S, Higgins CF, Ford RC (2005) Three-dimensional structure of P-glycoprotein: the transmembrane regions adopt an asymmetric configuration in the nucleotide-bound state. J Biol Chem, 280, 2857–2862.
Seelig A, Blatter XL, Wohnsland F (2000) Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharmacol Ther, 38, 111–121.
Spiegel S, Milstien S (2003) Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol, 4, 397–407.
Sugawara T, Kinoshita M, Ohnishi M, Tsuzuki T, Miyazawa T, et al. (2004) Efflux of sphingoid bases by P-glycoprotein in human intestinal Caco-2 cells. Biosci Biotechnol Biochem, 68, 2541–2546.
Uchida Y, Itoh M, Taguchi Y, Yamaoka S, Umehara H, Ichikawa S, Hirabayashi Y, Holleran WM, Okazaki T (2004) Ceramide reduction and transcriptional up-regulation of glucosylceramide synthase through doxorubicin-activated Sp1 in drug-resistant HL-60/ADR cells. Cancer Res, 64, 6271–6279.
van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, et al. (1996) MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell, 87, 507–517.
van Weely S, Brandsma M, Strijland A, Tager JM, Aerts JM (1993) Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys Acta, 1181, 55–62.
Watanabe R, Wu K, Paul P, Marks DL, Kobayashi T, et al. (1998) Up-regulation of glucosylceramide synthase expression and activity during human keratinocyte differentiation. J Biol Chem, 273, 9651–9655.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Tokyo
About this chapter
Cite this chapter
van Meer, G., Egmond, M., Halter, D. (2006). Sphingolipids and Multidrug Resistance of Cancer Cells. In: Hirabayashi, Y., Igarashi, Y., Merrill, A.H. (eds) Sphingolipid Biology. Springer, Tokyo. https://doi.org/10.1007/4-431-34200-1_20
Download citation
DOI: https://doi.org/10.1007/4-431-34200-1_20
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-34198-7
Online ISBN: 978-4-431-34200-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)